Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Mise à jour : Il y a 4 ans
Référence : NCT00819091

Femme et Homme

Extrait

Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.


Critère d'inclusion

  • Diabetes Mellitus, Type 2


Liens